{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T13:40:13Z","timestamp":1740836413973,"version":"3.38.0"},"reference-count":33,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1370,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1177\/0091270010388651","type":"journal-article","created":{"date-parts":[[2011,1,6]],"date-time":"2011-01-06T03:24:11Z","timestamp":1294284251000},"page":"1704-1711","source":"Crossref","is-referenced-by-count":10,"title":["Effects of Clopidogrel on the Pharmacokinetics of Sibutramine and Its Active Metabolites"],"prefix":"10.1002","volume":"51","author":[{"given":"Jung-Woo","family":"Bae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon-Gon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,12]]},"reference":[{"key":"10.1177\/0091270010388651-BIB1|cit1","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0278-5846(88)90003-6","article-title":"The pharmacology of sibutramine hydrochloride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down-regulation","volume":"12","author":"Buckett","year":"1988","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1177\/0091270010388651-BIB2|cit2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0028-3908(89)90048-8","article-title":"The contribution of metabolites to the rapid and potent down-regulation of rat cortical beta-adrenoceptors by the putative antidepressant sibutramine hydrochloride","volume":"28","author":"Luscombe","year":"1989","journal-title":"Neuropharmacology"},{"key":"10.1177\/0091270010388651-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/00003495-199856060-00019","article-title":"Sibutramine. A review of its contribution to the management of obesity","volume":"56","author":"McNeely","year":"1998","journal-title":"Drugs"},{"key":"10.1177\/0091270010388651-BIB4|cit4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-2999(02)01423-1","article-title":"The discovery and status of sibutramine as an anti-obesity drug","volume":"440","author":"Luque","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1177\/0091270010388651-BIB5|cit5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0014-2999(00)00216-8","article-title":"Enantioselective behavioral effects of sibutramine metabolites","volume":"397","author":"Glick","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1177\/0091270010388651-BIB6|cit6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1467-789X.2007.00425.x","article-title":"Sibutramine-associated adverse effects: a practical guide for its safe use","volume":"9","author":"Florentin","year":"2008","journal-title":"Obes Rev"},{"key":"10.1177\/0091270010388651-BIB7|cit7","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1381\/096089202321088327","article-title":"Sibutramine warning: hypertension and cardiac arrhythmias reported [editorial]","volume":"12","author":"Deitel","year":"2002","journal-title":"Obes Surg"},{"key":"10.1177\/0091270010388651-BIB8|cit8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2125.2006.02574.x","article-title":"QT interval prolongation associated with sibutramine treatment","volume":"61","author":"Harrison-Woolrych","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1177\/0091270010388651-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1345\/aph.1L129","article-title":"Sibutramine-associated QT interval prolongation and cardiac arrest","volume":"42","author":"Ernest","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1177\/0091270010388651-BIB10|cit10","unstructured":"Follow-up to the November 2009 Early communication about an ongoing safety review of sibutramine, marketed as Meridia http:www.fda.govDrugsDrugSafetyPostmarketDrugSafetyInformationforPatientsandProvidersDrugSafetyInformationforHeathcareProfessionalsucm198206.htm"},{"key":"10.1177\/0091270010388651-BIB11|cit11","unstructured":"Meridia (sibutramine hydrochloride) Follow-up to an early communication about an ongoing safety review http:www.fda.govSafetyMedWatchSafetyInformationSafetyAlertsforHumanMedicalProductsucm198221.htm"},{"key":"10.1177\/0091270010388651-BIB12|cit12","unstructured":"Questions and answers on the suspension of medicines containing sibutramine http:www.ema.europa.eupdfshumanreferralsibutramineSibutramineQ&A80817909en.pdf"},{"key":"10.1177\/0091270010388651-BIB13|cit13","unstructured":"Meridia (sibutramine) label information Abbott Laboratories http:www.accessdata.fda.govdrugsatfdadocslabel2009020632s032lbl.pdf"},{"key":"10.1177\/0091270010388651-BIB14|cit14","first-page":"1019","article-title":"Sibutramine: dose response and plasma metabolite concentrations in weight loss","volume":"34","author":"Kaiser","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"10.1177\/0091270010388651-BIB15|cit15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1124\/jpet.103.056127","article-title":"Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine","volume":"308","author":"Richter","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1177\/0091270010388651-BIB16|cit16","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2133\/dmpk.23.412","article-title":"Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine","volume":"23","author":"Hagihara","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1177\/0091270010388651-BIB17|cit17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/dmd.108.022988","article-title":"Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel","volume":"37","author":"Nishiya","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010388651-BIB18|cit18","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3109\/00498250903191427","article-title":"Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel","volume":"39","author":"Nishiya","year":"2009","journal-title":"Xenobiotica"},{"key":"10.1177\/0091270010388651-BIB19|cit19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clpt.2005.02.010","article-title":"Effect of clopidogrel and ticlopidine on cytochrome P450 2B6 activity as measured by bupropion hydroxylation","volume":"77","author":"Turpeinen","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010388651-BIB20|cit20","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0091270009333016","article-title":"Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms","volume":"49","author":"Chen","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1177\/0091270010388651-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1124\/dmd.108.020727","article-title":"Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes","volume":"36","author":"Bae","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010388651-BIB22|cit22","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0026-895X(25)09788-3","article-title":"Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese","volume":"46","author":"Morais","year":"1994","journal-title":"Mol Pharmacol"},{"key":"10.1177\/0091270010388651-BIB23|cit23","doi-asserted-by":"crossref","first-page":"15419","DOI":"10.1016\/S0021-9258(17)40694-6","article-title":"The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans","volume":"269","author":"Morais","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1177\/0091270010388651-BIB24|cit24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clpt.2005.10.002","article-title":"A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants","volume":"79","author":"Sim","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1177\/0091270010388651-BIB25|cit25","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/FPC.0b013e328045c4fb","article-title":"Genetic polymorphisms of CYP2B6 affect the pharmacokinetics\/pharmacodynamics of cyclophosphamide in Japanese cancer patients","volume":"17","author":"Nakajima","year":"2007","journal-title":"Pharmacogenet Genomics"},{"key":"10.1177\/0091270010388651-BIB26|cit26","first-page":"1480","article-title":"CYP2B6 and CYP2C19 as the major enzymes responsible for the metabolism of selegiline, a drug used in the treatment of Parkinson's disease, as revealed from experiments with recombinant enzymes","volume":"29","author":"Hidestrand","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010388651-BIB27|cit27","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1124\/dmd.104.002428","article-title":"Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study","volume":"33","author":"Obach","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010388651-BIB28|cit28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0090-9556(24)02975-1","article-title":"CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes","volume":"32","author":"Ram\u00edrez","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1177\/0091270010388651-BIB29|cit29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/clpt.2009.145","article-title":"Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects","volume":"86","author":"Kim","year":"2009","journal-title":"Clin Pharmacol Ther"},{"journal-title":"J Clin Pharmacol","article-title":"Effect of CYP2B6 genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects [published online ahead of print March 29, 2010]","author":"Chung","key":"10.1177\/0091270010388651-BIB30|cit30"},{"key":"10.1177\/0091270010388651-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/jms.1082","article-title":"Metabolite profile of sibutramine in human urine: a liquid chromatography-electrospray ionization mass spectrometric study","volume":"41","author":"Link","year":"2006","journal-title":"J Mass Spectrom"},{"key":"10.1177\/0091270010388651-BIB32|cit32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1467-789x.2000.00020.x","article-title":"An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action","volume":"1","author":"Nisoli","year":"2000","journal-title":"Obes Rev"},{"key":"10.1177\/0091270010388651-BIB33|cit33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/sj.ijo.0802887","article-title":"Influence of sibutramine on blood pressure: evidence from placebo-controlled trials","volume":"29","author":"Jordan","year":"2005","journal-title":"Int J Obes (Lond)"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270010388651","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1177\/0091270010388651\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T13:05:39Z","timestamp":1740834339000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/0091270010388651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2011,12]]}},"URL":"https:\/\/doi.org\/10.1177\/0091270010388651","relation":{},"ISSN":["0091-2700"],"issn-type":[{"type":"print","value":"0091-2700"}],"subject":[],"published":{"date-parts":[[2011,12]]}}}